Navigation Links
DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME
Date:10/17/2007

as found no significant issues in the treatment of patients with Medidur over the past 18 months in the recruitment phase of this pivotal study," said pSivida Limited Managing Director, Dr. Paul Ashton.

Currently, 7.5 percent of the US population is diabetic. Over time, almost all diabetics will develop some form of diabetic retinopathy, of which diabetic macular edema is the primary cause of vision loss. There are currently more than 500,000 people with DME in the United States and this number is expected to exceed 700,000 by the year 2010; approximately 75,000 new cases of DME are diagnosed each year.

About Alimera Sciences Inc.

Alimera Sciences Inc., an Atlanta, GA. venture backed company, specializes in the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions. Alimera is currently conducting a Phase 3 clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. For more information, please visit http://www.alimerasciences.com

About pSivida Limited

pSivida, a Boston, MA. based global drug delivery company, is committed to the biomedical sector. Retisert(R) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur(TM) for diabetic macular edema is licensed to Alimera Sciences and is in Phase 3 clinical trials. pSivida has a worldwide collaborative research and license agreement w
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Vitamin E supports Female Hearts
2. Injection supports Heart Devices
3. Study supports vegetable diet
4. Study supports century-old cancer theory
5. Google Supports Indians Novel Literacy Drive
6. Actor Anil Kapoor Supports Birth Registration Cause
7. AMA Supports Tax Penalty for Uninsured Americans
8. Church Supports HIV Test Before Marriage
9. EHRVA Supports EHR Product Certification
10. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
11. Bush Supports Restriction to ‘Morning–After’ Pll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , , , ... , LOUISVILLE, Ky., July 23 University of Louisville physicians ... Hospital in Louisville, KY, on July 17, 2009. The procedure is part ... treat heart disease. , , ...
... SAN DIEGO, July 23 Orexigen Therapeutics, Inc. ... priced an underwritten public offering of 10,000,000 shares of its ... proceeds, after estimated underwriting discounts and commissions and estimated expenses, ... a 30-day option to purchase up to an additional 1,500,000 ...
... Ohio, July 23 Estimates place the prevalence of physical ... of the global adult population according to THE ORTHOPAEDIC ... , , "Our sources indicate ... increased 25 percent over the past ten years, and those ...
... DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology ... is pleased to announce that it has been granted ... per "MIT China" requirements, from the "China Medical City" ... half years. , The operation facility will harbor all ...
... , , , ... TELEHOUSE America ( www.telehouse.com ) ... exchanges, and managed IT services, today announced it is offering ... prevention (DLP) consulting services as part of its Manage-E ...
... , , , ... Media, LLC., a new media and publishing company, today announced the ... a weekly web digest devoted to covering the ideas, technologies, business ... on opportunities for progress in healthcare, Healthspottr delivers select, forward-thinking content ...
Cached Medicine News:Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 2Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 3
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Dec. 7, 2010 Graymark Healthcare, Inc. (Nasdaq: ... of substantially all the assets of its ApothecaryRx,s retail ... ApothecaryRx operated 18 pharmacies across five states. ... business of providing comprehensive care for sleep disorders, primarily ...
... NEW YORK, Dec. 7, 2010 The NuVal™ ... (ActiveHealth®), a provider of evidence-based health information technology ... to bring new tools online to help ActiveHealth ... http://photos.prnewswire.com/prnh/20100119/NE39897LOGO) Beginning in December, NuVal,s nutrition ...
Cached Medicine Technology:Graymark Healthcare to Focus on Treatment of Sleep Disorders with Completed Sale of Independent Pharmacy Business Assets to Walgreens 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 3
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
... The new Synchron LXi 725 clinical ... with highly accurate immunoassay testing capabilities, ... handling on a single platform. After ... automatically repeated for optimal quality assurance. ...
...
...
Medicine Products: